Immuron Limited stock is up 3.59% since 30 days ago. The next earnings date is Dec 15, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 6 December’s closed higher than November.
Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.